Form 4: Biogen Director Eric Rowinsky Receives Stock Grant

Biogen Inc. director Eric K. Rowinsky was granted 1,505 restricted stock units as part of his compensation package.

Summary

• Director Eric K. Rowinsky acquired 1,505 restricted stock units (RSUs) of Biogen Inc. common stock.
• The transaction occurred on June 9, 2026, at a price of $0 per share, representing an equity grant.
• Following this transaction, the director's total beneficial ownership of common stock increased to 25,844 shares.
• The RSUs are scheduled to vest on the earlier of the next annual meeting or the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Standard market risks associated with equity ownership and potential volatility in Biogen Inc. share price.

Future Outlook

The restricted stock units are set to vest on the earlier of the next annual meeting or June 9, 2027.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between leadership and shareholder interests.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with standard compensation practices for large-cap pharmaceutical and biotech companies like Amgen, Gilead, and Eli Lilly.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• Vesting of the 1,505 restricted stock units on the earlier of the next annual meeting or June 9, 2027.

Key Dates

Keywords

Biogen, BIIB, Director, Insider Trading, Form 4, Equity Compensation